The role of hypertension in bromocriptine-related puerperal intracranial hemorrhage.
The spate of medicolegal inquiries following the disqualification of Parlodel (bromocriptine mesylate) by the Food and Drug Administration for postpartum ablactation, uncovered previously unreported side effects associated with its postpartum administration. In 1994, bromocriptine mesylate was withdrawn from the market as a milk suppressant. Since this time, over a dozen cases of postpartum intracranial hemorrhages associated with its use have been reported. We describe three additional cases of postpartum intracranial hemorrhage related to bromocriptine usage. One patient, previously normotensive, developed hypertension and a headache; initial CT was normal, but CT 24 h later demonstrated intracranial hemorrhage. This suggests that the blood-pressure elevation was drug-induced and was the cause, rather than the consequence, of bromocriptine-related intracranial hemorrhage.
Kirsch
C
C
Department of Radiology, University Hospital C-320, 150 Bergen St, Newark, NJ 07103, USA. Tr1386@aol.com
Iffy
L
L
Zito
G E
GE
McArdle
J J
JJ
D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging; D001971:Bromocriptine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D020299:Intracranial Hemorrhage, Hypertensive / Q000139:chemically induced* / Q000000981:diagnostic imaging; D007774:Lactation / Q000187:drug effects; D011644:Puerperal Disorders / Q000139:chemically induced* / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed
D001971:Bromocriptine